Member Info for chique

I have reduced consultants fees and other expenses by quite a bit - I don't know if I am correct in doing this so really a guess

This is my estimate for y/e 22 - I like this companies product and would like to invest and so am welcoming the input

Sales Revenue - 5,407,500 ( based on 2021 sales price)
Cost of sales - 1,968,000 ( based on 2021 cost price )
Gross Profit - 3,439,500

Basic Costs
accounting fees - 150,000
advertising - 245,000
directors - 788,000
consultants - 200,000
legal - 20,000
wages - 359,000
public company costs - 219,000
rent - 25,000
travel - 485,000
other expenses - 450,000
Total basic expense estimate 2,941,000

profit after basic expenses 498,500

I know they have mentioned a possible price increase for 2022 , but there may be increased costs also

T1995 - The statement of 40,000 breakeven was given on a cash accounting basis

I was looking at the total income vs the costs of directors , travelling expenses etc , those 2 alone are 50% of total revenue ( not profit ) and the 200k office consumables baffles me.

That's as maybe but to have
Last year a profit Gross profit of 1,241,520
then
Directors fees 788k
Consultant fees 516k
advertising 245k
Legal fees 43k
Wages 359k
Public company costs 219k
Travel expenses 485k
Other expenses 685k - just rolls off the tongue as if it were just petty cash

With the guidance of 85k tons this surely is still a loss

These figures above bear no relation to the revenue of the company and I am wondering how all this money is spent for such a small company

Really needs this with AISC top end of 1590

Looking at company for first time - seems to have high overheads relative to it's turnover with losses each year and also on last update

Rax , got a few higher than I wanted but all part of an average , would like more but will wait for a drop , otherwise will go with what I have. THX.V volume looks good today 150% daily average after 1 hour

Canter Fitzgerald recently increased their holding from 1.9% to just over 5% , they have dedicated healthcare researchers - they are also big with SPACS

Will be interesting to see if they start to build on their current holding.

In the UK, 90,000 babies are admitted to NICU units each year, and 80-85% of them receive antibiotics. Genedrive's rapid genetic test can be completed in less than 30 minutes, allowing for correct treatment decision on antibiotics to be made within one hour of admission, as required by the UK's National Institute of Clinical Excellence (NICE)

Inspiration Healthcare Group plc (AIM: IHC), the global medical technology company, is pleased to announce that it has entered into a contract with genedrive plc (AIM: GDR), the near patient molecular diagnostics company, to distribute its Antibiotic Induced Hearing Loss test (Genedrive® MT-RNR1) in the UK and Ireland. It is expected that the scope of the contract between genedrive and Inspiration Healthcare will be expanded over time to engage Inspiration Healthcare's specialty network of over 50 neonatal focussed sub-distributors around the world.

rax , I had not quite finished accumulating in the 14's and below
Segun has 4 million options at 12 canadian cents expiring on the 16th , as well as a couple of million for other directors at 12 cents.

I wouldn't mind if some of these shares came to market and weighed on the price a bit until I am fully loaded

Interesting comment you make about Barrick , Rio and Thor

Segun has extensive contacts and relationships in Nigeria and there could well be a great deal of synergy between Thor and Barrick , maybe Rio

he now has shares at 17.9

For about 1/2 the market maker has not been able to sell 2000 or over - even now at 17p cannot get quote

added a few more early this morning - looking good

THX.V moves on quite low volumes - but nice to see it up

What about the toxin removal and need to use a lot less of the drugs - for expensive - off patent drugs

Yes welcome. We made a bit of leeway for 2 months but looks like we are on course now after as course correction :-)

If not a spark it will add some confidence as Canter have a team of healthcare section researchers